Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A11QVV0
Tue, 28.06.2022
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Reports Outcome of the Annual General Meeting 2022
Ladenburg, Germany, 28 June 2022 – Heidelberg Pharma AG (FSE: HPHA) announced that the shareholders of the Company approved the resolutions of the administration with large majorities (ranged from 98.49% to 99.99%) during the virtual Annual General Meeting today:
[ … ]
Tue, 28.06.2022
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Reports Outcome of the Annual General Meeting 2022
Ladenburg, Germany, 28 June 2022 – Heidelberg Pharma AG (FSE: HPHA) announced that the shareholders of the Company approved the resolutions of the administration with large majorities (ranged from 98.49% to 99.99%) during the virtual Annual General Meeting today:
[ … ]
Mon, 09.05.2022
Heidelberg Pharma AG
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT.
Ad hoc announcement - Inside information pursuant to Article 17 MAR
Heidelberg Pharma AG and Partner H [ … ]
Thu, 28.04.2022
Heidelberg Pharma AG
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2022
- Start of clinical trial with HDP-101 in multiple myeloma
- Financing commitment of up to EUR 36 million obtained from main shareholder dievini
- Signing of a strategic partnership with Huadong Medicine with an overall volume of up to one billion US dollars
- Fin [ … ]
Thu, 07.04.2022
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma to Present New Data on its Proprietary ATAC(R) Technology Platform at the AACR Annual Meeting 2022
Ladenburg, Germany, 7 April 2022 - Heidelberg Pharma AG (FSE: HPHA) announced today that it will present preclinical data on its proprietary Amanitin-based ATAC(R) technology at the American Association for Cancer Res [ … ]
Thu, 24.03.2022
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma announces financial figures for fiscal year 2021 and provides business update
- Start of clinical trial with HDP-101 in multiple myeloma
- Signing of strategic partnership with Huadong Medicine
- Successful financing activities
- Financial figures in line with adjusted forecast
- Conference call to be held on 24 Ma [ … ]
Thu, 10.03.2022
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Receives Milestone Payment from Partner Magenta for Dosing the First Patient with MGTA-117
Ladenburg, Germany, 10 March 2022 - Heidelberg Pharma AG (FSE: HPHA) today announced that its cooperation partner Magenta Therapeutics, Cambridge, MA, USA, (Magenta; NASDAQ: MGTA) has dosed the first patient with the developm [ … ]
Mon, 28.02.2022
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment
- Heidelberg Pharma grants Huadong exclusive license to develop and commercialize HDP-101 and HDP-103 in Asia[1] (excluding Japan), plus exclusive opt-in rights for two more pipeline candidates, with a total deal value of up to USD 930 million [ … ]
Sun, 27.02.2022
Heidelberg Pharma AG
Ad hoc announcement - Inside information pursuant to Article 17 MAR
Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment
- Heidelberg Pharma grants Huadong exclusive license to develop and commercialize HDP-101 and HDP-103 in Asia[1] (excluding Japan), plus exclusive opt-in rights for two more pipeline candida [ … ]
Thu, 17.02.2022
Heidelberg Pharma AG
Ad hoc announcement - Inside information pursuant to Article 17 MAR
Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini
Ladenburg, Germany, 17 February 2022 - Heidelberg Pharma AG (FSE: HPHA) today announced that it has secured a financing commitment in the amount of up to EUR 36 million from its main shareholder d [ … ]